Clinicopathologic features and prognostic implications of NOK/STYK1 protein expression in non-small cell lung cancer

BMC Cancer

Xiao-Fei Li¹  Zhi-Pei Zhang¹  Xiao-Long Yan¹  Jian Wang¹  Qiang Lu¹  Wei-Miao Li¹  Peng Chen¹ 

[1]Department of thoracic surgery, Tangdu hospital, Fourth Military Medical University, Xi’an, China

关键词: Immunohistochemistry;    Prognosis;    Survival;    NSCLC;    Lung cancer;    Oncogene;    NOK;   

Others  :  858718
DOI  :  10.1186/1471-2407-14-402

 received in 2013-11-01, accepted in 2014-05-30,  发布年份 2014

【 摘 要 】

Background

The expression of novel oncogenic kinase (NOK), a member of the protein tyrosine kinase (PTK) family, has been observed in several human malignancies including non-small cell lung cancer (NSCLC). However, the clinic relevance of NOK expression in NSCLC remains unclear.

Methods

In this study, NOK expression in tumor cells was assessed using immunohistochemical methods in 191 patients with resected NSCLC. The association of NOK expression with clinicopathological parameters, including the Ki-67 labeling index (LI), was also evaluated. Kaplan-Meier survival analysis and Cox proportional hazards models were used to estimate the effect of NOK expression on survival.

Results

Data showed that NOK was expressed in 75.4% and 14.1% of cancer lesions and corresponding adjacent non-cancerous tissue, respectively. Out of all the clinicopathological factors analyzed, NOK expression was significantly correlated with the grade of tumor differentiation (P = 0.035), pTNM stage (P = 0.020), lymphatic metastasis (P = 0.005) and high Ki-67 LI (P < 0.001). NOK positive NSCLC patients had a significantly shorter survival time (P = 0.004, Log-rank test) and the prognostic significance of NOK expression was apparent in squamous cell carcinoma patients (P = 0.022). Multivariate analysis indicated that NOK expression may be an independent prognostic factor in NSCLC (hazard ratio [HR], 1.731; P = 0.043).

Conclusions

Our results indicate that NOK expression is of clinical significance and can serve as a prognostic biomarker in NSCLC.

【 授权许可】

   
2014 Chen et al.; licensee BioMed Central Ltd.

【 图 表 】

【 参考文献 】

• [1]Reungwetwattana T, Weroha SJ, Molina JR: Oncogenic Pathways, Molecularly Targeted Therapies, and Highlighted Clinical Trials in Non–Small-Cell Lung Cancer (NSCLC). Clinical Lung Cancer 2012, 13:252-266.
• [2]Siegel R, Naishadham D, Jemal A: Cancer statistics, 2012. CA Cancer J Clin 2012, 62:10-29.
• [3]Pfannschmidt J, Muley T, Bulzebruck H, Hoffmann H, Dienemann H: Prognostic assessment after surgical resection for non-small cell lung cancer: experiences in 2083 patients. Lung Cancer 2007, 55:371-377.
• [4]Ye X, Ji C, Huang Q, Cheng C, Tang R, Xu J, Zeng L, Dai J, Wu Q, Gu S, Xie Y, Mao Y: Isolation and characterization of a human putative receptor protein kinase cDNA STYK1. Mol Biol Rep 2003, 30:91-96.
• [5]Liu L, Yu XZ, Li TS, Song LX, Chen PL, Suo TL, Li YH, Wang SD, Chen Y, Ren YM, Zhang SP, Chang ZJ, Fu XY: A novel protein tyrosine kinase NOK that shares homology with platelet- derived growth factor/fibroblast growth factor receptors induces tumorigenesis and metastasis in nude mice. Cancer Res 2004, 64:3491-3499.
• [6]Chen Y, Li YH, Chen XP, Gong LM, Zhang SP, Chang ZJ, Zhang XF, Fu XY, Liu L: Point mutation at single tyrosine residue of novel oncogene NOK abrogates tumorigenesis in nude mice. Cancer Res 2005, 65:10838-10846.
• [7]Moriai R, Kobayashi D, Amachika T, Tsuji N, Watanabe N: Diagnostic relevance of overexpressed NOK mRNA in breast cancer. Anticancer Res 2006, 26:4969-4973.
• [8]Amachika T, Kobayashi D, Moriai R, Tsuji N, Watanabe N: Diagnostic relevance of overexpressed mRNA of novel oncogene with kinase-domain (NOK) in lung cancers. Lung Cancer 2007, 56:337-340.
• [9]Jackson KA, Oprea G, Handy J, Kimbro KS: Aberrant STYK1 expression in ovarian cancer tissues and cell lines. J Ovarian Res 2009, 2:15. BioMed Central Full Text
• [10]Kondoh T, Kobayashi D, Tsuji N, Kuribayashi K, Watanabe N: Overexpression of serine threonine tyrosine kinase 1/novel oncogene with kinase domain mRNA in patients with acute leukemia. Exp Hematol 2009, 37:824-830.
• [11]Zhang Z, Jiang T, Deng Y, Wang P, Wang J, Gu Z, Han Y, Wang Y, Zhao J, Chang Z, Li X: Expression and its Clinical Significance of NOK, EGFR in NSCLC. Zhongguo Fei Ai Za Zhi 2009, 12:983-988.
• [12]Li J, Wu F, Sheng F, Li YJ, Jin D, Ding X, Zhang S: NOK/STYK1 interacts with GSK-3beta and mediates Ser9 phosphorylation through activated Akt. FEBS Lett 2012, 586:3787-3792.
• [13]Goldstraw P, Crowley J, Chansky K, Giroux DJ, Groome PA, Rami-Porta R, Postmus PE, Rusch V, Sobin L: The IASLC Lung Cancer Staging Project: proposals for the revision of the TNM stage groupings in the forthcoming (seventh) edition of the TNM Classification of malignant tumours. J Thorac Oncol 2007, 2:706-714.
• [14]Blume-Jensen P, Hunter T: Oncogenic kinase signalling. Nature 2001, 411:355-365.
• [15]Hubbard SR, Miller WT: Receptor tyrosine kinases: mechanisms of activation and signaling. Curr Opin Cell Biol 2007, 19:117-123.
• [16]Muller-Tidow C, Diederichs S, Bulk E, Pohle T, Steffen B, Schwable J, Plewka S, Thomas M, Metzger R, Schneider PM, Brandts CH, Berdel WE, Serve H: Identification of metastasis-associated receptor tyrosine kinases in non-small cell lung cancer. Cancer Res 2005, 65:1778-1782.
• [17]Madhusudan S, Ganesan TS: Tyrosine kinase inhibitors in cancer therapy. Clinical Biochemistry 2004, 37:618-635.
• [18]Wu M, Zhao J, Song SW, Zhuo M, Wang X, Bai H, Wang S, Yang L, An T, Zhang Y, Duan J, Wang Y, Guo Q, Liu X, Liu N, Wang J: EGFR mutations are associated with prognosis but not with the response to front-line chemotherapy in the Chinese patients with advanced non-small cell lung cancer. Lung Cancer 2010, 67:343-347.
• [19]Zinner RG, Kim J, Herbst RS: Non-small cell lung cancer clinical trials with trastuzumab: their foundation and preliminary results. Lung Cancer 2002, 37:17-27.
• [20]Lee MY, Chou CY, Tang MJ, Shen MR: Epithelial-mesenchymal transition in cervical cancer: correlation with tumor progression, epidermal growth factor receptor overexpression, and snail up-regulation. Clin Cancer Res 2008, 14:4743-4750.
• [21]Luo J: Glycogen synthase kinase 3beta (GSK3beta) in tumorigenesis and cancer chemotherapy. Cancer Lett 2009, 273:194-200.
• [22]Doble BW, Woodgett JR: Role of glycogen synthase kinase-3 in cell fate and epithelial-mesenchymal transitions. Cells Tissues Organs 2007, 185:73-84.
• [23]Li YH, Wang YY, Zhong S, Rong ZL, Ren YM, Li ZY, Zhang SP, Chang ZJ, Liu L: Transmembrane helix of novel oncogene with kinase-domain (NOK) influences its oligomerization and limits the activation of RAS/MAPK signaling. Mol Cells 2009, 27:39-45.
• [24]Kim EK, Choi E-J: Pathological roles of MAPK signaling pathways in human diseases. Biochim Biophys Acta (BBA) - Molecular Basis of Disease 2010, 1802:396-405.
• [25]Schubbert S, Shannon K, Bollag G: Hyperactive Ras in developmental disorders and cancer. Nat Rev Cancer 2007, 7:295-308.
• [26]Chen P, Zhang ZP, Jin HT, Liu T, Li XF: Impact of STYK1/NOK gene transfection on the migration and invasion of lung adenocarcinoma cell line. Chin J Cancer Prev Treat 2011, 18:564-567.
• [27]Liu T, Zhang ZP, Li XF: Effect of NOK over expression on proliferation of lung adenocarcinoma cell SPC-A-1. Modern Oncology 2012, 20:1327-1330.
• [28]Kwak EL, Bang YJ, Camidge DR, Shaw AT, Solomon B, Maki RG, Ou SH, Dezube BJ, Janne PA, Costa DB, Varella-Garcia M, Kim WH, Lynch TJ, Fidias P, Stubbs H, Engelman JA, Sequist LV, Tan W, Gandhi L, Mino-Kenudson M, Wei GC, Shreeve SM, Ratain MJ, Settleman J, Christensen JG, Haber DA, Wilner K, Salgia R, Shapiro GI, Clark JW, Iafrate AJ: Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer. N Engl J Med 2010, 363:1693-1703.
• [29]Mok TS, Wu YL, Thongprasert S, Yang CH, Chu DT, Saijo N, Sunpaweravong P, Han B, Margono B, Ichinose Y, Nishiwaki Y, Ohe Y, Yang JJ, Chewaskulyong B, Jiang H, Duffield EL, Watkins CL, Armour AA, Fukuoka M: Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. N Engl J Med 2009, 361:947-957.
• [30]Ding X, Jiang QB, Li R, Chen S, Zhang S: NOK/STYK1 has a strong tendency towards forming aggregates and colocalises with epidermal growth factor receptor in endosomes. Biochem Biophys Res Commun 2012, 421:468-473.